Literature DB >> 25661268

Myoclonic epilepsy in Down syndrome and Alzheimer disease.

J S Aller-Alvarez1, M Menéndez-González2, R Ribacoba-Montero3, M Salvado4, V Vega2, R Suárez-Moro5, M Sueiras6, M Toledo4, J Salas-Puig4, J Álvarez-Sabin4.   

Abstract

INTRODUCTION: Patients with Down syndrome (DS) who exhibit Alzheimer disease (AD) are associated with age. Both diseases with a common neuropathological basis have been associated with late-onset myoclonic epilepsy (LOMEDS). This entity presents electroencephalogram features as generalized polyspike-wave discharges.
METHOD: We present a series of 11 patients with the diagnosis of DS or AD who developed myoclonic seizures or generalized tonic-clonic seizures. In all cases, clinical and neuroimaging studies and polygraph EEG monitoring was performed.
RESULTS: In all cases, cognitive impairment progressed quickly after the onset of epilepsy causing an increase in the degree of dependence. The most common finding in the EEG was a slowing of brain activity with theta and delta rhythms, plus intercritical generalized polyspike-waves were objectified in eight patients. In neuroimaging studies was found cerebral cortical atrophy. The most effective drug in this series was the levetiracetam.
CONCLUSIONS: The association of generalized epilepsy with elderly DS represents an epiphenomenon in evolution which is associated with a progressive deterioration of cognitive and motor functions. This epilepsy has some electroclinical characteristics and behaves as progressive myoclonic epilepsy, which is probably related to the structural changes that characterize the evolutionary similarity of DS with AD. Recognition of this syndrome is important, since it has prognostic implications and requires proper treatment.
Copyright © 2014 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Demencia; Dementia; Down syndrome; Enfermedad de Alzheimer; Epilepsia mioclónica; Late-onset myoclonic epilepsy in Down syndrome; Myoclonic epilepsy; Síndrome de Down

Mesh:

Substances:

Year:  2015        PMID: 25661268     DOI: 10.1016/j.nrl.2014.12.008

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  7 in total

Review 1.  Neurologic complications of Down syndrome: a systematic review.

Authors:  Jonathan D Santoro; Dania Pagarkar; Duong T Chu; Mattia Rosso; Kelli C Paulsen; Pat Levitt; Michael S Rafii
Journal:  J Neurol       Date:  2020-09-12       Impact factor: 6.682

Review 2.  Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications.

Authors:  Miren Altuna; Gonzalo Olmedo-Saura; María Carmona-Iragui; Juan Fortea
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

Review 3.  Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.

Authors:  Panagiotis Zis; Andre Strydom
Journal:  Free Radic Biol Med       Date:  2017-09-01       Impact factor: 7.376

4.  Atypical electrophysiological and behavioral responses to diazepam in a leading mouse model of Down syndrome.

Authors:  Daniella B Victorino; Daniel J L L Pinheiro; Jonah J Scott-McKean; Sarah Barker; Melissa R Stasko; Jean Faber; Carla A Scorza; Alberto C S Costa
Journal:  Sci Rep       Date:  2021-05-04       Impact factor: 4.379

5.  Treatment of Epilepsy Associated with Common Chromosomal Developmental Diseases.

Authors:  Magdalena Budisteanu; Claudia Jurca; Sorina Mihaela Papuc; Ina Focsa; Dan Riga; Sorin Riga; Alexandru Jurca; Aurora Arghir
Journal:  Open Life Sci       Date:  2020-02-28       Impact factor: 0.938

6.  Dementia in People with Severe/Profound Intellectual (and Multiple) Disabilities: Practice-Based Observations of Symptoms.

Authors:  Maureen B G Wissing; Andrea S Fokkens; Roos Dijkstra; Johannes S M Hobbelen; Annette A J van der Putten; Peter P De Deyn; Aly Waninge; Alain D Dekker
Journal:  J Ment Health Res Intellect Disabil       Date:  2022-04-22

7.  A Longitudinal Study of Epileptic Seizures in Alzheimer's Disease.

Authors:  John Baker; Tina Libretto; William Henley; Adam Zeman
Journal:  Front Neurol       Date:  2019-12-04       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.